Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07217067 | A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation | PHASE2 | RECRUITING | 165 | — | — | Oct 28, 2025 | Sep 9, 2027 | May 18, 2026 | 38 | United States, Canada +5 |
Defined as the amount of time spent in atrial fibrillation as a proportion of the analyzable monitoring time
| Arm | Type | Description |
|---|---|---|
| PKN605 lower dose | EXPERIMENTAL | PKN605 is an oral formulation |
| PKN605 higher dose | EXPERIMENTAL | PKN605 is an oral formulation |
| Placebo | PLACEBO_COMPARATOR | Placebo is an oral formulation |
| Name | Type | Description |
|---|---|---|
| PKN605 | DRUG | PKN605 is an oral formulation |
| Placebo | OTHER | Matching placebo |
Inclusion Criteria: * Inclusions at Screening * Signed informed consent must be obtained prior to participation in the study * Male and female participants ≥ 18 years of age * History of at least 2 episodes of AF (atrial fibrillation or atrial flutter), at least one episode must be atrial fi...